Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
2000 1
2002 2
2004 1
2005 1
2008 2
2009 1
2011 3
2012 4
2013 2
2014 3
2016 2
2017 1
2020 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Monoamine oxidases A and B gene polymorphisms in migraine patients.
Filic V, Vladic A, Stefulj J, Cicin-Sain L, Balija M, Sucic Z, Jernej B. Filic V, et al. Among authors: vladic a. J Neurol Sci. 2005 Feb 15;228(2):149-53. doi: 10.1016/j.jns.2004.11.045. Epub 2004 Dec 24. J Neurol Sci. 2005. PMID: 15694196
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. Coles AJ, et al. Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1. Lancet. 2012. PMID: 23122650 Clinical Trial.
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA; CARE-MS I investigators. Cohen JA, et al. Lancet. 2012 Nov 24;380(9856):1819-28. doi: 10.1016/S0140-6736(12)61769-3. Epub 2012 Nov 1. Lancet. 2012. PMID: 23122652 Clinical Trial.
Platelet serotonin measures in migraine.
Jernej B, Vladić A, Cicin-Sain L, Hranilović D, Banović M, Balija M, Bilić E, Sucić Z, Vukadin S, Grgicević D. Jernej B, et al. Among authors: vladic a. Headache. 2002 Jul-Aug;42(7):588-95. doi: 10.1046/j.1526-4610.2002.02145.x. Headache. 2002. PMID: 12482210
23 results